|
报告导航:研究报告—
生命科学—制药医疗
|
2010年中国胰岛素行业研究报告 |
|
字数:2.4万 |
页数:59 |
图表数:69 |
中文电子版:5500元 |
中文纸版:2750元 |
中文(电子+纸)版:6000元 |
英文电子版:1400美元 |
英文纸版:1500美元 |
英文(电子+纸)版:1700美元 |
编号:JMH004
|
发布日期:2011-01 |
附件:下载 |
|
|
2009年,中国胰岛素市场规模约为53亿元,但仍不到全球市场规模的6%。目前中国是全球糖尿病第一大国,糖尿病患者已达9200万人,加之中国糖尿病患者整体治疗率不足三成,且人均胰岛素使用量偏低,仅为美国糖尿病患者人均使用量的0.8%,所以中国胰岛素市场潜力巨大。 胰岛素行业属于高技术含量行业范畴。中国基因工程人胰岛素产业化还基本处于起步阶段,生产成本高、生产规模小等特点使其国际竞争力甚弱,这也就造成了进口胰岛素垄断中国市场的现象。2010年1-9月三大制药巨头诺和诺德、礼来和赛诺菲安万特合占中国胰岛素市场90.6%的份额,而中国最大的本土企业通化东宝占比仅3.7%。另外,不断有新的企业进入中国胰岛素市场,比如香港联邦制药、德国拜耳等。 图:2010年1-9月中国胰岛素市场竞争企业及其市场份额 来源:IMS,水清木华研究中心 本报告不仅重点分析了胰岛素行业整体及其细分市场的市场现状、竞争格局、发展方向等,还详细分析了丹麦诺和诺德、美国礼来、法国赛诺菲安万特三家外资胰岛素生产企业以及中国本土比较有规模的胰岛素生产企业的经营状况和发展前景。 丹麦诺和诺德是全球胰岛素行业的龙头,也是中国胰岛素行业的龙头;2008年诺和诺德占中国重组人胰岛素市场的83.4%,占中国胰岛素类似物市场的52.2%。美国礼来是第二位进入中国胰岛素市场的医药巨头,2008年占中国重组人胰岛素市场的12.3%,占中国胰岛素类似物市场的7.7%;礼来还进一步加紧布局中国市场,2009年投资超过4000万美元在苏州进行胰岛素扩建工程。法国赛诺菲安万特是全球第一个生产甘精胰岛素类似物的企业,2008年占中国胰岛素类似物市场的36.1%。 吉林通化东宝是中国最大的重组人胰岛素生产厂家;2010年通化东宝胰岛素原料药产能为3000公斤,胰岛素制剂产能为7000万瓶。北京甘李药业是通化东宝旗下的控股公司,与赛诺菲安万特并列成为全球仅有的两家生产甘精胰岛素类似物的企业。江苏万邦制药是中国动物胰岛素细分市场的龙头企业,2009年,江苏万邦在中国动物胰岛素市场上的占有率超过80%,另外,万邦制药生产的动物胰岛素已进入国家基本药物目录。
In 2009, China’s insulin market size reached up to RMB5.3 billion, but
still accounted for less than 6% of the global market. China has the
world’s most diabetes patients, which is 92 million at present. In
addition, the overall treatment rate of Chinese diabetes patients is
less than 30%, and the per capita consumption of insulin is low, which
is only about 0.8% of that of American patients. Therefore, China’s
insulin market has great potential. The insulin industry is a
high-tech industry. China’s genetically engineered human insulin is
still in the initial stage of industrialization, and has weak global
competitiveness due to its high production cost and small production
scale, which has led to the monopoly of imported insulin in China. In
the first three quarters of 2010, Novo Nordisk, Eli Lilly and
Sanofi-Aventis accounted for 90.6% of China’s insulin market, while
Tonghua Dongbao, the largest domestic company, only accounted for 3.7%.
In addition, more and more enterprises are entering the Chinese insulin
market, such as The United Laboratories of Hong Kong and Bayer of
Germany. Enterprises in China’s Insulin Market by Market Share, Jan.-Sep.2010 Source: IMS, ResearchInChina The
report not only analyzes the status quo, competition pattern and
development direction of the insulin industry as a whole and its market
segments, but also makes a detailed analysis of the operation and
development prospect of three foreign insulin producers including Novo
Nordisk, Eli Lilly and Sanofi-Aventis as well as several large-scale
domestic insulin producers. Novo Nordisk of Denmark is an
insulin industry leader in both China and the world; it accounted for
83.4% of China’s recombinant human insulin market and 52.2% of China’s
insulin analog market in 2008. Eli Lilly of the United States is
the second pharmaceutical giant entering in China’s insulin market. It
accounted for 12.3% of China’s recombinant human insulin market and 7.7%
of China’s insulin analog market in 2008; it is expanding its presence
in China. It invested over USD40 million in an insulin expansion project
in Suzhou in 2009. Sanofi-Aventis of France is the world's
first producer of insulin glargine analog, and accounted for 36.1% of
China’s insulin analog market in 2008. Jilin Tonghua Dongbao is
China's largest producer of recombinant human insulin; in 2010, its
insulin API capacity was 3,000 kg and the insulin dosage form capacity
was 70 million bottles in 2010. Beijing Gan & Lee
Pharmaceutical is a company controlled by Tonghua Dongbao. Gan & Lee
and Sanofi Aventis are the world’s only two insulin glargine analog
manufacturers. Jiangsu Wanbang Biopharmaceuticals is a leading
animal insulin enterprise in China, and occupied more than 80% of
China’s animal insulin market in 2009. In addition, its animal insulin
has been selected into the national catalog of essential drugs.
第一章 胰岛素行业概述 1.1 定义和分类 1.2 产业链
第二章 中国胰岛素市场运行的国际环境 2.1 发展现状 2.1.1 市场规模 2.1.2 新药研发方向 2.1.3 生产工艺 2.2 市场供需 2.3 竞争格局 2.4 发展前景 2.4.1 糖尿病愈演愈烈 2.4.2 竞争药物或替代疗法 2.4.3 市场规模预测
第三章 中国胰岛素市场现状和展望 3.1 市场现状 3.2 市场供需 3.3 竞争格局 3.3.1 外资企业垄断 3.3.2 新加入企业 3.4 行业毛利率及价格 3.5 政策环境分析 3.6 发展前景 3.6.1 胰岛素人均使用量将会提高 3.6.2 胰岛素市场占有率增大
第四章 中国胰岛素市场进出口分析 4.1 胰岛素及其盐进出口分析 4.1.1 胰岛素及其盐出口 4.1.2 胰岛素及其盐进口 4.2 未配剂量含胰岛素的药品进出口分析 4.3 已配剂量含胰岛素的药品进出口分析 4.3.1 已配剂量含胰岛素的药品出口 4.3.2 已配剂量含胰岛素的药品进口
第五章 中国胰岛素生产行业内优势企业 5.1 通化东宝 5.1.1 公司简介 5.1.2 经营状况 5.1.3 营销策略 5.1.4 发展动态 5.1.5 甘李药业 5.2 诺和诺德制药有限公司 5.2.1 公司简介 5.2.2 经营状况 5.2.3 在华经营状况 5.2.4 发展动态 5.3 礼来 5.3.1 公司简介 5.3.2 经营状况 5.3.3 在华经营状况 5.3.4发展动态 5.4 赛诺菲安万特 5.4.1 公司简介 5.4.2 经营状况 5.4.3 在华经营状况 5.4.4 发展动态 5.5 江苏万邦生化制药有限公司 5.5.1 公司简介 5.5.2 经营状况 5.5.3 发展前景
1. Overview of Insulin Industry
1.1 Definition & Classification
1.2 Industry Chain
2. International Environment for the Operation of China’s Insulin Market
2.1 Current Development
2.1.1 Market Size
2.1.2 R&D Direction of New Drugs
2.1.3 Production Process
2.2 Market Supply and Demand
2.3 Competition Pattern
2.4 Development Prospect
2.4.1 Increasingly Serious Diabetes Problem
2.4.2 Competitive Drugs or Alternative Therapies
2.4.3 Market Forecast
3. Status Quo & Prospect of China’s Insulin Market
3.1 Market Status
3.2 Market Supply & Demand
3.3 Competition Pattern
3.3.1 Foreign Monopoly
3.3.2 Newcomers
3.4 Industry Gross Margin and Price
3.5 Policy Environment
3.6 Development Prospect
3.6.1 Per Capita Consumption of Insulin will Increase
3.6.2 Market Share of Insulin will Increase
4. Import and Export of China's Insulin Market
4.1 Import & Export of Insulin and its Salts
4.1.1 Export
4.1.2 Import
4.2 Import & Export of Insulin-containing Drugs in Unfinished Dosage Form
4.3 Import& Export of Insulin-containing Drugs in Finished Dosage Form
4.3.1 Export
4.3.2 Import
5. Advantageous Enterprises in China’s Insulin Production Industry
5.1 Tonghua Dongbao
5.1.1 Profile
5.1.2 Operation
5.1.3 Marketing Strategy
5.1.4 Development Trend
5.1.5 Gan & Lee Pharmaceutical
5.2 Novo Nordisk
5.2.1 Profile
5.2.2 Operation
5.2.3 Operation in China
5.2.4 Development Trend
5.3 Eli Lilly
5.3.1 Profile
5.3.2 Operation
5.3.3 Operation in China
5.3.4 Development Trend
5.4 Sanofi-Aventis
5.4.1 Profile
5.4.2 Operation
5.4.3 Operation in China
5.4.4 Development Trend
5.5 Wanbang Biopharmaceuticals
5.5.1 Profile
5.5.2 Operation
5.5.3 Development Prospect
表:糖尿病类型 表:胰岛素制剂分类及其特点(按技术水平) 表:胰岛素制剂分类及其代表产品(按作用时间) 图:胰岛素行业产业链 图:2008-2010年全球糖尿病药物和胰岛素药物市场规模 图:2010年全球糖尿病药物分类及其占比 表:2006-2009年吸入型胰岛素制剂的研发动态 图:2009-2016年全球胰岛素泵市场规模 表:重组人胰岛素生产载体及其特点 图:2005-2009年全球糖尿病患者人数 表:2009年全球胰岛素原料药理论需求规模 图:2009年糖尿病患者人数最多的前三名国家 图:2009年全球胰岛素市场前三大竞争企业 表:2009年全球胰岛素类似物市场主要生产企业销售额 表:截至2010年5月在研1型糖尿病免疫治疗药物 表:胰高血糖素样多肽1(GLP-1)相关药物 表:截至2010年12月胰岛素细胞移植研究机构及其进展 图:2007-2017年全球1型糖尿病治疗药物市场规模 图:2008-2009年中国胰岛素药物市场规模 表:2009年中国22城市典型医院部分胰岛素产品采购金额及同比增长 图:2010年1-9月中国胰岛素市场竞争企业及其市场份额 图:2008年中国重组人胰岛素细分市场竞争企业及其占比 图:2008年中国胰岛素类似物细分市场竞争企业及其占比 表:2010年中国当前或潜在的胰岛素生产企业 图:2008-2010年中国通化东宝重组人胰岛素产品营业毛利率 表:2009-2010年中国常见胰岛素产品价格 表:中国医保目录2009年版收录胰岛素 图:2009年不同国家糖尿病患者平均胰岛素利用量 图:2007-2009年中国胰岛素和口服降糖药市场占有率 图:2008-2010年中国胰岛素及其盐出口金额及其价格 图:2010年1-11月中国胰岛素及其盐出口国家及其占比 图:2008-2010年中国胰岛素及其盐进口金额及其价格 图:2010年1-11月中国胰岛素及其盐进口国家及其占比 图:2010年1-11月中国未配剂量含胰岛素的药品累计出口金额 图:2010年1-11月中国未配剂量含胰岛素的药品出口国家及其占比 图:2008-2010年中国已配剂量含胰岛素的药品出口金额及其价格 图:2010年1-11月中国已配剂量含胰岛素的药品出口国家及其占比 图:2008-2010年中国已配剂量含胰岛素的药品进口金额及其价格 图:2010年1-11月中国已配剂量含胰岛素的药品进口国家及其占比 图:2008-2010年通化东宝主营业务收入 图:2008-2010年通化东宝重组人胰岛素产品营业收入及利润 图:2008-2010年通化东宝销售费用及其同比增长 表:2009-2010年通化东宝主要动态 图:2008-2009年北京甘李药业医院终端采购金额 图:2008-2010年诺和诺德总体营业收入及营业利润 表:2010年上半年诺和诺德主营业务分类及其产品 图:2008-2010年诺和诺德重组人胰岛素和胰岛素类似物营业收入及同比增长 表:2009年诺和诺德中国区公司及其业务 图:2007-2009年诺和诺德全球各个大区销售收入比较 表:2009-2011年诺和诺德主要动态 表:截至2009年礼来公司全球主要上市产品 图:2007-2010年礼来公司总体营业收入及利润 图:2009年礼来公司各部门营业收入及其占比 图:2007-2010年礼来胰岛素产品Humulin和Humalog营业收入 表:2010年礼来中国公司及其业务 图:2007-2008年礼来苏州制药营业收入、营业费用及利润 表:2008-2013年礼来公司主要动态 表:2009年赛诺菲-安万特糖尿病产品 图:2007-2010年赛诺菲安万特主营业务收入及其利润 图:2008-2010年赛诺菲安万特胰岛素相关产品营业收入 表:2010上半年胰岛素相关产品(分地区)营业收入 表:2010年赛诺菲安万特中国公司 表:截至2010年赛诺菲在中国工厂新建情况 表:赛诺菲-安万特胰岛素产品领域发展动态 表:江苏万邦生化医药控股公司情况 表:2010年江苏万邦公司胰岛素产品 图:2007-2010年江苏万邦医药主营业务净利润 图:2008-2009年江苏万邦生产胰岛素的单位能耗 表:2009-2010年江苏万邦发展动态
Types of Diabetes Classification and Characteristics of Insulin Dosage Forms (by Technology) Classification and Typical Products of Insulin Dosage Forms (by Effective Time) Insulin Industry Chain Global Market Scale of Diabetes Drugs and Insulin Drugs, 2008-2010 Classification of Global Diabetes Drugs, 2010 R & D of Inhaled Insulin Dosage Form, 2006-2009 Global Insulin Pump Market Scale, 2009-2016 Recombinant Human Insulin Production Carrier and its Characteristics Global Number of Diabetes Patients, 2005-2009 Global Theoretic Demand for Insulin API, 2009 Top Three Countries by Number of Diabetes Patients, 2009 Top Three Enterprises in Global Insulin Market, 2009 Sales of Major Producers in Global Insulin Analog Market, 2009 Drugs for the Immune Therapy of Type I Diabetes under Development, May 2010 Glucagon-like Peptide 1 (GLP-1)-related Drugs Insulin Cell Transplantation Research Institutions and Progress, Dec. 2010 Global Market Scale of the Drugs for the Treatment of Type I Diabetes, 2007-2017 China’s Insulin Drug Market Scale, 2008-2009 Purchase Prices and YoY Growth of Some Insulin Products of Typical Hospitals in 22 Cities of China, 2009 Enterprises in China's Insulin Market by Market Share, Jan.-Sep. 2010 Enterprises in China’s Recombinant Human Insulin Market by Market Share, 2008 Enterprises in China's Insulin Analog Market by Market Share, 2008 Current or Potential Insulin Producers in China, 2010 Operating Gross Margin of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010 Prices of Common Insulin Products in China, 2009-2010 Insulin Included in the Health Insurance Directory of China, 2009 Average Insulin Utilization of Diabetes Patients by Country, 2009 Market Occupancy of China’s Insulin and Oral Hypoglycemic Drugs, 2007-2009 China’s Export Value and Prices of Insulin and its Salts, 2008-2010 China’s Export of Insulin and its Salts by Destination, Jan.-Nov. 2010 China’s Import Value and Prices of Insulin and its Salts, 2008-2010 China’s Import of Insulin and its Salts by Country of Origin, Jan.-Nov. 2010 China’s Cumulative Export Value of Insulin-containing Drugs in Unfinished Dosage Form, Jan.-Nov. 2010 China’s Export of Insulin-containing Drugs in Unfinished Dosage Form by Destination, Jan.-Nov. 2010 China’s Export Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010 China’s Export of Insulin-containing Drugs in Finished Dosage Form by Destination, Jan.-Nov. 2010 China’s Import Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010 China’s Import of Insulin-containing Drugs in Finished Dosage Form by Country of Origin, Jan.-Nov. 2010 Operating Income of Tonghua Dongbao, 2008-2010 Operating Income and Profit of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010 Sales Expenses and YoY Growth of Tonghua Dongbao, 2008-2010 Development of Tonghua Dongbao, 2009-2010 Hospital Procurement Amount of Beijing Gan & Lee Pharmaceutical, 2008-2009 Total Operating Income and Operating Profit of Novo Nordisk, 2008-2010 Main Businesses and Products of Novo Nordisk, H1 2010 Operating Income and YoY Growth of Recombinant Human Insulin and Insulin Analog of Novo Nordisk, 2008-2010 Novo Nordisk in China, 2009 Sales Revenue of Novo Nordisk by Region, 2007-2009 Development of Novo Nordisk, 2009-2011 Major Products of Eli Lilly, 2009 Total Operating Income and Profit of Eli Lilly, 2007-2010 Operating Income of Eli Lilly by Division, 2009 Operating Income of Humulin and Humalog of Eli Lilly, 2007-2010 Eli Lilly in China, 2010 Operating Income, Operating Expenses and Profit of Eli Lilly Suzhou Pharmaceutical, 2007-2008 Development of Eli Lilly, 2008-2013 Diabetes Products of Sanofi–Aventis, 2009 Operating Income and Profit of Sanofi-Aventis, 2007-2010 Operating Income of Insulin-related Products of Sanofi-Aventis, 2008-2010 Operating Income of Insulin-related Products of Sanofi-Aventis by Region, H1 2010 Sanofi-Aventis in China, 2010 Plants of Sanofi-Aventis in China, 2010, Sanofi-Aventis’ Development in the Field of Insulin Products Profile of Jiangsu Wanbang Pharmaceuticals Insulin Products of Jiangsu Wanbang Pharmaceuticals, 2010 Net Income of Jiangsu Wanbang Pharmaceuticals by Main Business, 2007-2010 Unit Energy Consumption of Insulin Production of Jiangsu Wanbang Pharmaceuticals, 2008-2009 Development of Jiangsu Wanbang Pharmaceuticals, 2009-2010
如果这份报告不能满足您的要求,我们还可以为您定制报告,请 留言说明您的详细需求。
|